
Innoviva (INVA) Stock Forecast & Price Target
Innoviva (INVA) Analyst Ratings
Bulls say
Innoviva is a company with a strong portfolio of royalty healthcare assets and a diversified business model that includes both commercialized products and strategic investments. Their stable and established target markets, along with multiple already approved and marketed products, provide for a positive outlook on the company's financial prospects. The company's recent acquisitions and partnerships, as well as their strong cash position and low debt, suggest potential for long-term growth and success in the healthcare industry.
Bears say
Innoviva is facing a modest top-line miss due to softened royalty-based revenue, leading to downgraded full-year revenue forecasts through 2027. However, the company's bottom-line results were significantly boosted by gains from its investment portfolio, indicating a lack of primary reliance on its core royalty assets. Additionally, Innoviva's reliance on its internally marketed products and strategic investments may not be sustainable or lucrative in the long term, making the stock a risky investment with limited upside potential.
This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.
Innoviva (INVA) Analyst Forecast & Price Prediction
Start investing in Innoviva (INVA)
Order type
Buy in
Order amount
Est. shares
0 shares